Increases of pentraxin 3 plasma levels in patients with Parkinson's disease§

Authors

  • Ho-Won Lee MD, PhD,

    1. Department of Neurology, Brain Science and Engineering Institute, Kyungpook National University School of Medicine, Daegu, Korea
    Search for more papers by this author
  • Jihye Choi BS,

    1. Department of Pharmacology, Brain Science and Engineering Institute, CMRI, Kyungpook National University School of Medicine, Daegu, Korea
    Search for more papers by this author
  • Kyoungho Suk PhD

    Corresponding author
    1. Department of Pharmacology, Brain Science and Engineering Institute, CMRI, Kyungpook National University School of Medicine, Daegu, Korea
    • Department of Pharmacology, Kyungpook National University School of Medicine, 101 Dong-In, Joong-gu, Daegu, 700-422, Korea
    Search for more papers by this author

  • Funding agencies: This work was supported by the Basic Science Research Program through the National Research Foundation (NRF) of Korea as funded by the Ministry of Education, Science and Technology (MEST) (No. 2010-0029460).

  • Relevant conflicts of interest/financial disclosures: Nothing to report.

  • §

    Full financial disclosures and author roles may be found in the online version of this article.

Abstract

Pentraxin 3 is a prototypic long pentraxin. Pentraxin 3 is a soluble recognition receptor that is involved in innate immunity and the inflammatory response. Its expression is induced by proinflammatory signals. The aim of this study was to compare the plasma levels of pentraxin 3 in healthy subjects and patients with neurodegenerative disorders such as mild cognitive impairment, Alzheimer's disease, and Parkinson's disease (PD). Thirty-nine patients with mild cognitive impairment, 75 patients with Alzheimer's disease, 66 patients with PD, and 41 healthy elderly controls were recruited for this study. We performed an extensive battery of neuropsychological tests, including a Mini–Mental Status Examination, clinical dementia rating, and the Unified Parkinson's Disease Rating Scale. A variety of clinical information was collected from the administered semistructured questionnaire. Plasma pentraxin 3 levels were measured using a specific enzyme-linked immunosorbent assay. Plasma pentraxin 3 levels were significantly higher in the PD patients than in the patients with mild cognitive impairment and Alzheimer's disease and in the control subjects. Plasma pentraxin 3 levels in the PD patients were correlated with activities of daily living (r = 0.368; P = .003) and motor function (r = 0.358; P = .004). Plasma pentraxin 3 levels could be a new biochemical marker for PD, and they may be associated with the severity of motor dysfunction and other clinical symptoms in PD patients. © 2011 Movement Disorder Society

Ancillary